web analytics

Sunshine BioPharma (SBFM) Surges on $2 Million Funding; Four Potential Inhibitors

0

Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is running northbound after the Company announced it has received the first tranche of $250,000 as part of a committed minimum financing of $2 Million with RB Capital Partners Inc. The proceeds will be used for development of the Company’s recently announced Coronavirus treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer compound targeted for pancreatic cancer.

The $2 million funding commitment represents a huge vote of confidence in Sunshine Bio who recently completed the synthesis of four different potential inhibitors of Coronavirus protease. These compounds are based on the technology described in the Company’s recently filed patent application covering small molecules which can be used to treat Coronavirus infections, including SARS-CoV-2 the causative agent of COVID-19. Sunshine BioPharma (SBFM) has successfully synthesized four inhibitors to ward off and destroy coronavirus (COVID-19) and the mutation stages up to COVID-30 and recently submitted their patented formula to the FDA. There is a petition on https://petitions.whitehouse.gov/ for Sunshine Bio coronavirus treatment.

Sunshine Biopharma Inc. (SBFM) Stock Message Board - InvestorsHubSunshine Biopharma, Inc. (OTCMKTS:SBFM) operating out of Montral, Quebec, is a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications. Since inception, Sunshine Bio has been focused on the development of a small molecule called Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells. Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patents Number 8,236,935 and 10,272,065. Sunchine Bio has some revenues mainly from its Essential 9™ a dietary supplement in the form of tablets which contain a balanced formula of the 9 essential amino acids that the human body cannot make. On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma Inc. to manufacture and sell the Essential 9™ product. Essential 9™ is currently available on Amazon.com and Amazon.ca. In November 2019, the Company received Health Canada approval for another dietary supplement, a new Calcium-Vitamin D tablets. Health Canada issued NPN 80093432 through which it authorized Sunshine Bio to manufacture and sell the new Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin D™

SBFM – coronavirus: Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of COVID-19, the current ongoing pandemic that has claimed the lives of over 920,000 people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. More recently, Sunshine Biopharma announced that it has completed the synthesis of four such molecules and is currently testing their inhibitory activity on SARS-Cov-2 proteases in order to identify a lead compound for further development as a specific drug for treatment of COVID-19.

To Find out the inside Scoop on SBFM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

SBFMSunchinse Biopharma CEO Dr. Slilaty is an accomplished scientist and a highly skilled business executive. He received his Bachelor of Science degree in Genetics and Biochemistry from Cornell University and his Ph.D. in Molecular Biology & Biochemistry from the University of Arizona. Dr. Slilaty is a leader in the bioscience industry and is referenced in editorials, reviews and textbooks. His extensive contributions to science included the discovery of a new class of enzymes (IUBMB Enzyme: EC 3.4.21.88) and the development of key technology for the Human Genome Project (TrueBlue Cloning System). With a passion for medicine, he founded three biotech companies and took one public. The company he took public, Genomics One Corporation reached $1 billion market cap.

In August SBFM announced it has completed the synthesis of four different potential inhibitors of Coronavirus protease. These compounds are based on the technology described in the Company’s recently filed patent application covering small molecules which can be used to treat Coronavirus infections, including SARS-CoV-2 the causative agent of COVID-19. Next, Sunshine will evaluate the binding affinity of these molecules to the SARS-CoV-2 papain-like protease (PLpro), one of two virus encoded proteases essential for viral replication. In addition to cleaving the virus encoded polyprotein at three different sites to generate mature virus proteins, PLpro also cleaves certain host proteins resulting in suppression of the innate immune response thereby allowing the virus to multiply unhindered. Based on the binding affinity results, Sunshine will select a lead compound for further Anti-Coronavirus drug development.

On September 15 SBFM announced it has received the first tranche of $250,000 as part of a committed minimum financing of $2 Million with RB Capital Partners Inc. Pursuant to the financing agreement entered into as of September 8, 2020, RB Capital has agreed to provide funding to the Company in the form of convertible promissory notes. The Promissory Notes will bear interest at the rate of 5% per annum and will be fully convertible into shares of the Company’s Common Stock at a conversion price equal to the market value of the Company’s Common Stock on the applicable conversion date or $0.30 per share, whichever is greater. The Promissory Notes will have a maturity date of two years from the date of issuance and must be fully converted on or before the maturity date. Sunshine reserves the right to pay off any part or all of the Promissory Notes at any time without penalty. The minimum amount of funding that RB Capital has agreed to provide to the Company under these terms is $2,000,000, payable over the next three to six month period.

The proceeds will be used for development of the Company’s recently announced Coronavirus treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer compound targeted for pancreatic cancer.

Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are extremely pleased to have forged a relationship with RB Capital and believe that this is the beginning of a successful funding partnership. We are now well positioned to continue with the development of our life saving treatments with a funding partner alongside of us who sees the long-term vision of the Company.”

https://twitter.com/ElectTrader/status/1305895434876006400

 

We have a Monster Pick Coming. Subscribe Right Now!

Currently running northbound SBFM is an exciting story developing in small caps; the Company just received the first tranche of $250,000 as part of a committed minimum financing of $2 Million with RB Capital Partners Inc. The proceeds will be used for development of the Company’s recently announced Coronavirus treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer compound targeted for pancreatic cancer. SBFM recently completed the synthesis of four different potential inhibitors of Coronavirus protease. These compounds are based on the technology described in the Company’s recently filed patent application covering small molecules which can be used to treat Coronavirus infections, including SARS-CoV-2 the causative agent of COVID-19. We will be updating on SBFM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with SBFM.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in SBFM either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.